DOBMEIER ERIC 4

4 · Janux Therapeutics, Inc. · Filed Jun 12, 2026

AI-generated summary of this filing

Updated Jun 13, 2026

Janux (JANX) Director Eric Dobmeier Receives Stock Awards

What Happened

Eric Dobmeier, a director of Janux Therapeutics (JANX), reported two awards on 2026-06-11: 5,500 restricted stock units (RSUs) and a 15,500-share derivative award (option). Both were granted at $0.00 (no cash paid). These are company compensation awards, not open-market purchases or sales.

Key Details

Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely).
Grants: 5,500 RSUs (A) at $0.00; 15,500 derivative award (A) at $0.00.
Vesting: RSUs vest on the earlier of June 11, 2027 or the next annual meeting, subject to continuous service (Footnote F1). The derivative (option) vests in equal monthly installments over the 12 months after June 11, 2026, but will be fully vested by the next annual meeting if service continues (Footnote F2).
Shares owned after the transaction: not specified in the excerpted filing.
No immediate sale or cashless exercise reported; these are forward-looking compensation awards.

Context

Awards like RSUs and time-based options are common director compensation and do not necessarily signal an immediate trading view; they are typically intended for retention/compensation.
Because no purchase or sale occurred and no cash exchanged, this filing documents grant-based compensation rather than market-driven insider buying or selling.

Form 4

Period: 2026-06-11

Director

Transactions

Award
Common Stock
[F1]
2026-06-11+5,500→ 15,481 total
Award
Stock Option (right to buy)
[F2]
2026-06-11+15,500→ 15,500 total
Exercise: $13.66Exp: 2036-06-10→ Common Stock (15,500 underlying)

Footnotes (2)

[F1]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
[F2]The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Signature

/s/ James Pennington, Attorney-in-Fact|2026-06-12

1 file